Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.

Francesco Passiglia, Commendatore Oriana, Vitali Milena, Conca Raffaele

Risultato della ricerca: Article

3 Citazioni (Scopus)

Abstract

Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.
Lingua originaleEnglish
pagine (da-a)41-60
Numero di pagine20
RivistaFuture Oncology
Volume14
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. / Passiglia, Francesco; Oriana, Commendatore; Milena, Vitali; Raffaele, Conca.

In: Future Oncology, Vol. 14, 2018, pag. 41-60.

Risultato della ricerca: Article

Passiglia, Francesco ; Oriana, Commendatore ; Milena, Vitali ; Raffaele, Conca. / Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. In: Future Oncology. 2018 ; Vol. 14. pagg. 41-60.
@article{dad9d302cc1f4efe86f863ac44245d17,
title = "Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.",
abstract = "Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.",
author = "Francesco Passiglia and Commendatore Oriana and Vitali Milena and Conca Raffaele",
year = "2018",
language = "English",
volume = "14",
pages = "41--60",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.

AU - Passiglia, Francesco

AU - Oriana, Commendatore

AU - Milena, Vitali

AU - Raffaele, Conca

PY - 2018

Y1 - 2018

N2 - Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.

AB - Lung cancer has been historically considered a poorly immunogenic disease because of the few evidence of immune responses in affected patients and the limited efficacy of immunomodulating strategies. Recent understanding of the molecular mechanisms leading to cancer immune evasion has allowed the development of a new class of drugs called immune checkpoint inhibitors, which reactivate host responses with outstanding clinical benefits in a portion of patients with non-small-cell lung cancer. In this review, we briefly summarize the basis of immunogenicity and immune escape of cancer, with specific focus on non-small-cell lung cancer, mechanisms underlying immune checkpoint inhibitors efficacy and the most updated results on potential biomarkers, with the final aim of defining current unmet needs of immunotherapy in clinical practice.

UR - http://hdl.handle.net/10447/295576

M3 - Article

VL - 14

SP - 41

EP - 60

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -